Literature DB >> 18433784

Pigment epithelium-derived factor and interleukin-6 control prostate neuroendocrine differentiation via feed-forward mechanism.

Norm D Smith1, Frank Thilo Schulze-Hoepfner, Dorina Veliceasa, Stephanie Filleur, Sarah Shareef, Lijun Huang, Xue-Mei Huang, Olga V Volpert.   

Abstract

PURPOSE: PEDF (pigment epithelium-derived factor) promotes the differentiation and survival of neuronal cells, and expands the adult neuronal stem cell niche. In the prostate PEDF is suppressed by androgen with unclear physiological consequences. We report that PEDF induced the neuroendocrine differentiation of prostate cancer cells, which was accompanied by neurite outgrowth and chromogranin A expression.
MATERIALS AND METHODS: We performed neuroendocrine differentiation assay, Western blot analysis, immunostaining and reverse transcriptase-polymerase chain reaction in the human prostate cancer cell lines LNCaP, PC-3 and DU145, and the prostate epithelial strain RWPE-1 (ATCC).
RESULTS: Ectopic and endogenous PEDF caused neuroendocrine differentiation of prostate cancer cells, as manifested by neurite-like outgrowths and chromogranin A expression. The transdifferentiated cells expressed axonal and dendritic markers, as ascertained by immunoblotting for specific markers. Neuroendocrine cells formed multiple synaptophysin positive protrusions resembling dendritic spines and vesicles containing serotonin, pointing to possible synapse formation. The known transdifferentiating agent interleukin-6 induced PEDF secretion. Moreover, PEDF neutralizing antibodies abolished the transdifferentiation of interleukin-6 treated cells, suggesting an autocrine loop. Neurogenic events were independent of cyclic adenosine monophosphate. Instead, PEDF activated in this order RhoA, nuclear factor kappaB and Stat3. Inhibitors of the Rho, nuclear factor kappaB and STAT pathways abolished differentiation and synapse formation. Additionally, nuclear factor kappaB activation caused interleukin-6 expression.
CONCLUSIONS: We discovered that nuclear factor kappaB controls the formation of neuronal communications in the prostate due to PEDF. We defined a feed-forward loop, in which nuclear factor kappaB induction elicits Stat3 activation and pro-differentiating interleukin-6 expression causes the further expansion of neuroendocrine communications. Our findings point to the role of nuclear factor kappaB and PEDF in coordinated prostate development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18433784      PMCID: PMC2849797          DOI: 10.1016/j.juro.2008.01.081

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  20 in total

Review 1.  Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable?

Authors:  A Sciarra; G Mariotti; V Gentile; G Voria; A Pastore; S Monti; F Di Silverio
Journal:  BJU Int       Date:  2003-03       Impact factor: 5.588

2.  STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells .

Authors:  M T Spiotto; T D Chung
Journal:  Prostate       Date:  2000-02-15       Impact factor: 4.104

Review 3.  Neuroendocrine differentiation in prostate cancer.

Authors:  Amir H Shariff; M Hammad Ather
Journal:  Urology       Date:  2006-07       Impact factor: 2.649

Review 4.  Neuroendocrine pathogenesis in adenocarcinoma of the prostate.

Authors:  J Hansson; P A Abrahamsson
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

Review 5.  Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications.

Authors:  P A di Sant'Agnese
Journal:  Cancer       Date:  1992-07-01       Impact factor: 6.860

6.  Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas.

Authors:  Jennifer A Doll; Veronica M Stellmach; Noël P Bouck; Anders R J Bergh; Chung Lee; Lisa P Abramson; Mona L Cornwell; Michael R Pins; Jayme Borensztajn; Susan E Crawford
Journal:  Nat Med       Date:  2003-05-12       Impact factor: 53.440

7.  Interleukin-6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation.

Authors:  Qingcai Wang; Dimitris Horiatis; Jacek Pinski
Journal:  Int J Cancer       Date:  2004-09-10       Impact factor: 7.396

8.  NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.

Authors:  Ren Jie Jin; Yongqing Wang; Naoya Masumori; Kenichiro Ishii; Taiji Tsukamoto; Scott B Shappell; Simon W Hayward; Susan Kasper; Robert J Matusik
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

9.  Regulation of interleukin-6-mediated PI3K activation and neuroendocrine differentiation by androgen signaling in prostate cancer LNCaP cells.

Authors:  Shaozhen Xie; Hui-Kuan Lin; Jing Ni; Lin Yang; Liang Wang; P Anthony di Sant'Agnese; Chawnshang Chang
Journal:  Prostate       Date:  2004-06-15       Impact factor: 4.104

10.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.

Authors:  Shunyou Wang; Jing Gao; Qunying Lei; Nora Rozengurt; Colin Pritchard; Jing Jiao; George V Thomas; Gang Li; Pradip Roy-Burman; Peter S Nelson; Xin Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

View more
  13 in total

1.  Pigment epithelium-derived factor blocks tumor extravasation by suppressing amoeboid morphology and mesenchymal proteolysis.

Authors:  Omar Ladhani; Cristina Sánchez-Martinez; Jose L Orgaz; Benilde Jimenez; Olga V Volpert
Journal:  Neoplasia       Date:  2011-07       Impact factor: 5.715

2.  The PCa Tumor Microenvironment.

Authors:  Joseph L Sottnik; Jian Zhang; Jill A Macoska; Evan T Keller
Journal:  Cancer Microenviron       Date:  2011-07-05

Review 3.  The effects of PEDF on cancer biology: mechanisms of action and therapeutic potential.

Authors:  S Patricia Becerra; Vicente Notario
Journal:  Nat Rev Cancer       Date:  2013-03-14       Impact factor: 60.716

4.  Short pigment epithelial-derived factor-derived peptide inhibits angiogenesis and tumor growth.

Authors:  Yelena Mirochnik; Arin Aurora; Frank T Schulze-Hoepfner; Ahmed Deabes; Victor Shifrin; Richard Beckmann; Charles Polsky; Olga V Volpert
Journal:  Clin Cancer Res       Date:  2009-02-17       Impact factor: 12.531

Review 5.  PEDF and its roles in physiological and pathological conditions: implication in diabetic and hypoxia-induced angiogenic diseases.

Authors:  Xuemin He; Rui Cheng; Siribhinya Benyajati; Jian-xing Ma
Journal:  Clin Sci (Lond)       Date:  2015-06       Impact factor: 6.124

6.  Chronic intermittent hypoxia increases encoding pigment epithelium-derived factor gene expression, although not that of the protein itself, in the temporal cortex of rats.

Authors:  Guilherme Silva Julian; Renato Watanabe de Oliveira; Vanessa Manchim Favaro; Maria Gabriela Menezes de Oliveira; Juliana Cini Perry; Sergio Tufik; Jair Ribeiro Chagas
Journal:  J Bras Pneumol       Date:  2015 Jan-Feb       Impact factor: 2.624

Review 7.  Targeting neuroendocrine prostate cancer: molecular and clinical perspectives.

Authors:  Panagiotis J Vlachostergios; Christos N Papandreou
Journal:  Front Oncol       Date:  2015-02-02       Impact factor: 6.244

8.  P18 peptide, a functional fragment of pigment epithelial-derived factor, inhibits angiogenesis in hepatocellular carcinoma via modulating VEGF/VEGFR2 signalling pathway.

Authors:  Xin Wang; Peng Xiu; Fuhai Wang; Jingtao Zhong; Honglong Wei; Zongzhen Xu; Feng Liu; Jie Li
Journal:  Oncol Rep       Date:  2017-06-14       Impact factor: 3.906

9.  Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.

Authors:  T Nelius; D Martinez-Marin; J Hirsch; B Miller; K Rinard; J Lopez; W de Riese; S Filleur
Journal:  Cell Death Dis       Date:  2014-05-08       Impact factor: 8.469

Review 10.  Anti-tumor effects of pigment epithelium-derived factor (PEDF): implication for cancer therapy. A mini-review.

Authors:  Louiza Belkacemi; Shaun Xiaoliu Zhang
Journal:  J Exp Clin Cancer Res       Date:  2016-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.